SlideShare a Scribd company logo
GERIATRIC
SYNDROMES
FARHAD ZARGARI, MD, PHD
GERIATRIC SYNDROMES
GERIATRIC SYNDROMES
 1-Disability
 2-Dementia and Delirium
 3-Falls
 4-Poly-pharmacy
 5-Pressure Ulcers
 6-Urinary Incontinence
DISABILITY
1-LONGER LIVES AND DISABILITY
 Are we living healthier as well as longer lives, or are our
additional years spent in poor health? There is
considerable debate about this question among
researchers, and the answers have broad implications for
the growing number of older people around the world.
One way to examine the question is to look at changes
in rates of disability, one measure of health and function.
1-LONGER LIVES AND DISABILITY
 Disability is part of the human condition. Almost everyone
will be temporarily or permanently impaired at some
point in life, and those who survive to old age will
experience increasing difficulties in functioning.
1-LONGER LIVES AND DISABILITY
 Disability is the umbrella term for impairments, activity
limitations and participation restrictions, referring to the
negative aspects of the interaction between an
individual (with a health condition) and that individual’s
contextual factors (environmental and personal factors).
1-LONGER LIVES AND DISABILITY
 Disability is “an evolving concept”, also “disability results
from the interaction between persons with impairments
and attitudinal and environmental barriers that hinder
their full and effective participation in society on an
equal basis with others”. Defining disability as an
interaction means that “disability” is not an attribute of
the person.
1-LONGER LIVES AND DISABILITY
 Responses to disability have changed since the 1970s,
prompted largely by the self-organization of people with
disabilities, and by the growing tendency to see disability
as a human rights issue. Historically, people with
disabilities have largely been provided for through
solutions that segregate them, such as residential
institutions and special schools. Policy has now shifted
towards community and educational inclusion, and
medically- focused solutions have given way to more
interactive approaches recognizing that people are
disabled by environmental factors as well as by their
bodies.
1-LONGER LIVES AND DISABILITY
 Disability encompasses the child born with a congenital
condition such as cerebral palsy or the young soldier
who loses his leg to a land-mine, or the middle-aged
woman with severe arthritis, or the older person with
dementia, among many others.
DISABILITY AND HUMAN RIGHTS
 Disability is a human rights issue because:
 People with disabilities experience inequalities – for example,
when they are denied equal access to health care,
employment, education, or political participation because of
their disability.
 People with disabilities are subject to violations of dignity – for
example, when they are subjected to violence, abuse,
prejudice, or disrespect because of their disability.
 Some people with disability are denied autonomy – for
example, when they are subjected to involuntary sterilization,
or when they are confined in institutions against their will, or
when they are regarded as legally incompetent because of
their disability.
DISABILITY AND DEVELOPMENT
 Disability is a development issue, because of its
bidirectional link to poverty: disability may increase the
risk of poverty, and poverty may increase the risk of
disability. A growing body of empirical evidence from
across the world indicates that people with disabilities
and their families are more likely to experience
economic and social disadvantage than those without
disability.
1-LONGER LIVES AND DISABILITY
 Some researchers think there will be a decrease in the
prevalence of disability as life expectancy increases,
termed a “compression of morbidity.” Others see an
“expansion of morbidity”—an increase in the prevalence
of disability as life expectancy increases. Yet others
argue that, as advances in medicine slow the
progression from chronic disease to disability, severe
disability will lessen, but milder chronic diseases will
increase.
1-LONGER LIVES AND DISABILITY
 In the United States, between 1982 and 2001 severe
disability fell about 25 percent among those aged 65 or
older even as life expectancy increased. This very
positive trend suggests that we can affect not only how
long we live, but also how well we can function with
advancing age. Unfortunately, this trend may not
continue in part because of rising obesity among those
now entering older ages.
1-LONGER LIVES AND DISABILITY
 The analysis of the Global Burden of Disease estimates
that 15.3% of the world population (some 978 million
people of the estimated 6.4 billion in 2004 had
“moderate or severe disability”, while 2.9% or about 185
million experienced “severe dis- ability”. Among those
aged 0–14 years, the figures were 5.1% and 0.7%, or 93
million and 13 million children, respectively. Among those
15 years and older, the figures were 19.4% and 3.8%, or
892 million and 175 million, respectively.
1-LONGER LIVES AND DISABILITY
 Based on 2010 population estimates – 6.9 billion with 5.04
billion 15 years and over and 1.86 billion under 15 years –
and 2004 disability prevalence estimates (World Health
Survey and Global Burden of Disease) there were around
785 (15.6%) to 975 (19.4%) million persons 15 years and
older living with disability. Of these, around 110 (2.2%) to
190 (3.8%) million experienced significant difficulties in
functioning. Including children, over a billion people (or
about 15% of the world’s population) were estimated to
be living with disability.
1-LONGER LIVES AND DISABILITY
 Fig. 2.1. Global disability prevalence estimates from
different sources:
This figure compares the
population-weighted average
prevalence of disability for
high-income, middle- income,
and low-income countries
from multiple sources. The solid
grey bars show the average
prevalence based on
available data, the range lines
indicate the 10th and 90th
percentiles for available
country prevalence within
each income group. The data
used for this figure are not age
standardized and cannot be
directly compared with Table
2.1 and Table 2.3. WHS = World
Health Survey; GBD = the
1-LONGER LIVES AND DISABILITY
 Age-specific disability prevalence, derived from multi-
domain functioning levels in 59 countries, by country
income level and sex:
1-LONGER LIVES AND DISABILITY
 Age-specific disability prevalence, derived from multi-
domain functioning levels in 59 countries, by country
income level and sex:
1-LONGER LIVES AND DISABILITY
1-LONGER LIVES AND DISABILITY
 American adults reported worse health than did
European adults as indicated by the presence of chronic
diseases and by measures of disability. At all levels of
wealth, Americans were less healthy than their European
counterparts. Analyses of the same data sources also
showed that cognitive functioning declined further
between ages 55 and 65 in countries where workers left
the labor force at early ages, suggesting that
engagement in work might help preserve cognitive
functioning.
1-LONGER LIVES AND DISABILITY
 Prevalence of
Chronic Disease and
Disability among Men
and Women Aged
50-74 Years in the
United States,
England, and Europe:
2004
Source: Adapted from Avendano
M, Glymour MM, Banks J,
Mackenbach JP. Health
disadvantage in US adults aged 50
REHABILITATION
 Rehabilitation as “a set of measures that assist individuals
who experience, or are likely to experience, disability to
achieve and maintain optimal functioning in interaction
with their environments”. A distinction is sometimes made
between habilitation, which aims to help those who
acquire disabilities con- genitally or early in life to
develop maximal functioning; and rehabilitation, where
those who have experienced a loss in function are
assisted to regain maximal functioning.
DEMENTIA
2-THE BURDEN OF DEMENTIA
 Physicians often define dementia based on the criteria
given in the Diagnostic and Statistical Manual of Mental
Disorders (DSM). In 2013 the American Psychiatric
Association released the fifth edition of the DSM (DSM-5),
which incorporates dementia into the diagnostic
categories of major and mild neurocognitive disorders.
2-THE BURDEN OF DEMENTIA
 To meet DSM-5 criteria for major neurocognitive disorder,
an individual must have evidence of significant cognitive
decline (for example, decline in memory, language or
learning), and the cognitive decline must interfere with
independence in everyday activities (for example,
assistance may be needed with complex activities such
as paying bills or managing medications). To meet DSM-5
criteria for mild neurocognitive disorder, an individual
must have evidence of modest cognitive decline, but
the decline does not interfere with everyday activities
(individuals can still perform complex activities such as
paying bills or managing medications, but the activities
require greater effort).
2-THE BURDEN OF DEMENTIA
 Dementia is a syndrome due to disease of the brain –
usually of a chronic or progressive nature – in which there
is disturbance of multiple higher cortical functions,
including memory, thinking, orientation, comprehension,
calculation, learning capacity, language, and
judgment. Consciousness is not clouded. The
impairments of cognitive function are commonly
accompanied, and occasionally preceded, by
deterioration in emotional control, social behavior, or
motivation. This syndrome occurs in a large number of
conditions primarily or secondarily affecting the brain.
2-THE BURDEN OF DEMENTIA
 The cause of most dementia is unknown, but the final
stages of this disease usually means a loss of memory,
reasoning, speech, and other cognitive functions. The risk
of dementia increases sharply with age and, unless new
strategies for prevention and management are
developed, this syndrome is expected to place growing
demands on health and long term care providers as
population ages.
2-THE BURDEN OF DEMENTIA
 The disease is not easy to diagnose, especially in its early
stages. The memory problems, misunderstandings, and
behavior common in the early and intermediate stages
are often attributed to normal effects of aging,
accepted as personality traits, or simply ignored.
2-THE BURDEN OF DEMENTIA
 Many cases remain undiagnosed even in the
intermediate, more serious stages. A cross-national
assessment conducted by the Organization for
Economic Cooperation and Development (OECD)
estimated that dementia affected about 10 million
people in OECD member countries around 2000, just
under 7 percent of people aged 65 or older.
2-THE BURDEN OF DEMENTIA
2-THE BURDEN OF DEMENTIA
2-THE BURDEN OF DEMENTIA
2-THE BURDEN OF DEMENTIA
2-THE BURDEN OF DEMENTIA
2-THE BURDEN OF DEMENTIA
 Types of Dementia
 Alzheimer’s disease
 Vascular dementia=Post-stroke dementia
 Dementia with Lewy bodies (DLB)
 Frontotemporal lobar degeneration (FTLD)
 Mixed dementia
 Parkinson’s disease (PD) dementia
 CreutzfeldtJakob disease
 Normal pressure hydrocephalus
2-THE BURDEN OF DEMENTIA
 The total number of people with dementia worldwide in
2010 is estimated at 35.6 million and is projected to
nearly double every 20 years, to 65.7 million in 2030 and
115.4 million in 2050. The total number of new cases of
dementia each year worldwide is nearly 7.7 million,
implying one new case every four seconds.
2-THE BURDEN OF DEMENTIA
 The total estimated worldwide costs of dementia were
US$ 604 billion in 2010. In high-income countries, informal
care (45%) and formal social care (40%) account for the
majority of costs, while the proportionate contribution of
direct medical costs (15%) is much lower. In low-income
and lower-middle-income countries direct social care
costs are small, and informal care costs (i.e. unpaid care
provided by the family) predominate.
2-THE BURDEN OF DEMENTIA
 Alzheimer’s disease(AD) is the most common form of
dementia and accounted for between two-fifth and four
fifth of all dementia cases cited in the OECD report. More
recent analyses have estimated the worldwide number
of people living with AD/dementia at between 27 million
and 36 million. The prevalence of AD and other
dementias is very low at younger ages, then nearly
doubles with every five years of age after age 65.
2-THE BURDEN OF DEMENTIA
 In the OECD review, for example, dementia affected
fewer than 3 percent of those aged 65 to 69, but almost
30 percent of those aged 85 to 89. More than one-half of
women aged 90 or older had dementia in France and
Germany, as did about 40 percent in the United States,
and just under 30 percent in Spain.
2-THE BURDEN OF DEMENTIA
 The projected costs of caring for the growing numbers of
people with dementia are daunting. The 2010 World
Alzheimer Disease Report estimates that the total
worldwide cost of dementia exceeded US$600 billion in
2010, including informal care provided by family and
others, social care provided by community care
professionals, and direct costs of medical care. Family
members often play a key caregiving role, especially in
the initial stages of what is typically a slow decline. Ten
years ago, U.S. researchers estimated that the annual
cost of informal caregiving for dementia in the United
States was US$18 billion.
2-THE BURDEN OF DEMENTIA
 The complexity of the disease and the wide variety of
living arrangements can be difficult for people and
families dealing with dementia, and countries must cope
with the mounting financial and social impact. The
challenge is even greater in the less developed world,
where an estimated two-thirds or more of dementia
sufferers live but where few coping resources are
available.
2-THE BURDEN OF DEMENTIA
 Projections by World Alzheimer Disease Report suggest
that 115 million people worldwide will be living with
AD/dementia in 2050, with a markedly increasing
proportion of this total in less developed countries.
2-THE BURDEN OF DEMENTIA
 The Growth of
Numbers of People
with Dementia in High-
income Countries and
Low- and Middle-
income Countries:
2010-2050
Source: Alzheimer’s Disease International,
World Alzheimer Report, 2010.
GERIATRIC FALLS
HELP! I’VE FALLEN AND I CAN’T GET UP!
3-GERIATRIC FALLS
 Falls are the leading cause of external injuries.
 Most common in children less than 5 years old and adults 65
and older.
 Trauma is the 5th cause of death in those >65 years
 Falls are responsible for 70% of accidental deaths in
people over 75 years old.
 1/4 of the elderly people who fracture their hips die
within 6 months of the injury.
 35%-40% of people 65+ fall each year. Those who
fall are 2-3 times more likely to fall again.
 10%-20% of falls cause serious injuries.
3-GERIATRIC FALLS
 Falls are the leading cause of external injuries.
 Most common in children less than 5 years old and adults 65
and older.
 Trauma is the 5th cause of death in those >65 years.
 Falls are responsible for 70% of accidental deaths in
people over 75 years old.
 1/4 of the elderly people who fracture their hips die
within 6 months of the injury.
3-GERIATRIC FALLS
 Up to 20-30% of falls in older adults result in an injury
requiring medical care
 Most fractures in Medicare population are due to falls
 Falls in older adults are the leading cause of traumatic
brain injury
 Men have a higher rate of fatal falls (due to TBI)
 Women are more likely to have non-fatal falls
3-GERIATRIC FALLS
Age Group
First Leading
of Trauma Death
Second Leading
Cause of
Death
35 – 64
Motor Vehicle
36.8%
Falls
29.6%
65+
Falls
43.3%
Motor Vehicle
10.2%
3-GERIATRIC FALLS
 Consequences of Geriatric Falls
 Death
 Injury
 Fractures 10-15%
 Hip 1-2%
 Long Lie
 Fear of Falling
 Reduced Activity/Independence (25%)
3-GERIATRIC FALLS-HIP FRACTURE
 In 1996 more than 250,000 older Americans had
fractured hips.
 90% are associated with falls
 Excess of $10 billion
 Leading fall-related injury that results in hospitalization –
which are often prolonged and costly.
 What Happens After the Hip Fracture?
 One in four people that have a hip fracture that lived
independently before the fracture had to live in a nursing
home for a year afterward, according to the CDC.
 Some never recover their balance and strength.
 This can lead to depression and dementia and a downhill
spiral.
 Unfortunately 1/4 of the elderly people who fracture their hips
die within 6 months of the injury.
3-GERIATRIC FALLS-BRAIN INJURY
 Also a common injury following a fall
 Many elderly on “blood thinners”
 Symptoms may be subtle and not apparent at the time
of injury.
RISK FACTORS FOR FALLS
 Increased age
 Living alone
 Previous falls
 Use of a cane or walker
 Acute illness
 Reduced vision
 Glare intolerance
 Altered depth perception
 Decreased night vision
 Decline in peripheral vision
RISK FACTORS FOR FALLS
 CVA that results in hemiparesis, sensory and/or
motor function deficits.
 Decreased range of motion and flexibility in lower
legs and spine.
 Weakness
 Decreased step length (short shuffling steps)
 Alzheimer’s or dementia
 Arthritis
 Parkinson’s disease
 Foot problems
 Toenail length, callouses, bunions, deformities
RISK FACTORS FOR FALLS
 Difficulty rising from a chair
 Neurologic changes
 Slowed reaction times
 Diminished sensory awareness for light touch, vibration,
and temperature
 Decline in proprioception
 Decreased hearing
 Impaired speech discrimination
 Excessive cerumen accumulation
 Loss of high frequency tones
 Risky behaviors
RISK FACTORS FOR FALLS
 Medications
 Some antidepressants
 Sedatives
 Some antihypertensive and cardiac medications
 Hypoglycemic drugs
 Alcohol
3-GERIATRIC FALLS
 American Geriatrics Society: Most Common Intrinsic Fall
Risk Factors
 Muscle weakness: 4.4
 History of falls: 3.0
 Gait or balance deficit: 2.9
 Use of assistive device: 2.6
 Visual deficit: 2.5
 Arthritis: 2.4
 Depression: 2.2
 Cognitive impairment: 1.8
 Age over 80 years: 1.7
Data from AGS Panel on Falls Prevention. Guideline for the prevention of falls in older
persons. J Am Geriatr Soc 2001;49(5):664–72.
4-POLY-PHARMACY
POLYPHARMACY-DEFINITION
 Polypharmacy means “many drugs.”
 In practice, polypharmacy refers to the use of more
medication than is clinically indicated or warranted.
 Polypharmacy can result in a gradual accumulation of
side effects and/or adverse drug reactions, which
negatively effects elders’ health and well-being.
POLYPHARMACY-DEFINITION
 Polypharmacy is the use of four or more medications by
a patient, generally adults aged over 65 years.
Polypharmacy (ie, the use of multiple medications
and/or the administration of more medications than are
clinically indicated, representing unnecessary drug use) is
common among the elderly, affecting about 40% of
older adults living in their own homes.
POLYPHARMACY-DEFINITION
 Although polypharmacy can be appropriate, it is more
often inappropriate. Concerns about polypharmacy
include increased adverse drug reactions, drug
interactions, prescribing cascade, and higher costs.
Polypharmacy is often associated with a decreased
quality of life, decreased mobility and cognition.
POLYPHARMACY-DEFINITION
 Patients at greatest risk for negative polypharmacy
consequences include the elderly, psychiatric patients,
patients taking five or more drugs concurrently, those
with multiple physicians and pharmacies, recently
hospitalized patients, individuals with concurrent
comorbidities, low educational level, and those with
impaired vision or dexterity.
POLYPHARMACY-DEFINITION
 The literature review found that polypharmacy continues
to increase and is a known risk factor for important
morbidity and mortality.
POLYPHARMACY-DEFINITION
 Older adults comprise 12% of the U.S. population, but use
35% of the prescription medications and 50 percent of
the over-the-counter medications.
 The average medication usage for persons over 65 is:
 2 to 6 prescription drugs, plus …
 1 to 3.4 over-the-counter medicines.
 In 2011, 58 percent of adults 65 years or older reported
taking 5 or more medications and 18% reported taking
10 or more (Slone Epidemiology Center).
 The average American senior spends $870 annually for
pharmaceuticals.
POLYPHARMACY-CAUSES
 1-Age:
 Community elders- 90% > 1med; 40% > 5meds; 12% > 10meds.
 Highest number of drugs per person in greater than 80 year
olds
POLYPHARMACY-CAUSES
 2-Chronic Diseases:
 Increased prevalence of somatic complaints and chronic
disease
POLYPHARMACY-CAUSES
 3-Drug Regimen Changes:
 New meds, different doses…
 Changes from generic to brand- nomenclature, color and/or
shape
POLYPHARMACY-CAUSES
 4-Providers – Patients Relationship:
 The more the providers and physician visits, the more the
number of medications patients take.
 2/3 of all physician visits end with a prescription.
 Expectations to receive medication is growing from the patient
side.
 Shortage in communicating with PCP about medications
changes.
 Self-treatment
POLYPHARMACY-COMPLICATIONS
 Polypharmacy leads to:
 More adverse drug reactions.
 Decreased adherence to drug regimens.
 Higher rates of disease symptomatology.
 (Unnecessary) drug expenses.
 All of the above contribute to client distress and poorer
quality of life, which are of great concerns.
POLYPHARMACY-COMPLICATIONS
 Polypharmacy leads to:
 More adverse drug reactions (ADR).
 Decreased adherence to drug regimens.
 Higher rates of disease symptomatology.
 (Unnecessary) drug expenses.
 All of the above contribute to client distress and poorer
quality of life, which are of great concerns.
ADVERSE DRUG REACTIONS
 Side effects: considered minor enough to allow
continuation of therapy.
 Adverse Drug Reactions (ADRs): May necessitate
discontinuation of drug and require treatment of adverse
event.
ADVERSE DRUG REACTIONS
 An adverse drug reaction (ADR) is defined as the
unwanted, negative consequences associated with the
use of a medications or medications.
 Over 100,000 deaths a year are attributed to adverse
drug reactions, making ADRs the fourth leading cause of
death in the U.S. (Lazarou, Pomeranz, & Corey, 2009).
 Other examples of ADRs include:
 Peptic ulcers
 Anemia
 Deceased white blood cell production (which increases
infection risk)
 Liver damage
 Kidney damage
 Confusion/drowsiness (which can lead to falls and subsequent
injuries)
ADVERSE DRUG REACTIONS
 About 3 to 7% of all hospital admissions in the United
States are for treatment of adverse drug reactions.
 Elderly 7 times more likely to have unwanted side effect
and 2-3 times more likely to have ADRs
 Adverse drug reactions occur during 10 to 20% of
hospital admissions, and about 10 to 20% of these
reactions are severe.
 The most consistent risk factor for an adverse drug
reactions is:
 The number of drugs being taken.
 Multiple medications is the factor most strongly
correlated with increased risk of ADRs. Exponential
increase in ADRs with addition of more drugs to a
ADVERSE DRUG REACTIONS
1
10
100
0 2 4 6 8 10 12 14 16 18 20
number of drugs taken
percentofpatientswithADR
ADVERSE DRUG REACTIONS
 Other risk factors for ADRs include:
 Having six or more chronic diseases.
 Taking twelve or more doses of medication (of any type) per
day.
 Taking nine or more medications total.
 Having had a prior adverse drug reaction.
 Being older than 85 years (this is important because persons 85
and older are the fastest growing segment of the population).
 Having decreased kidney function.
ADVERSE DRUG REACTIONS
 Drugs most frequently associated with adverse reactions
in the elderly:
 Psychotropic drugs, especially benzodiazepines (valium,
ativan)
 Anti-hypertensive agents (blood pressure medications)
 Diuretics
 Digoxin (a heart medication)
 NSAIDS (Non-steroidal anti-inflammatory drugs, i.e. aspirin,
Aleve, celebrex)
 Corticosteroids (i.e. prednisone - often used to treat arthritis)
 Warfarin (coumadin - a blood thinner for treating blood clots)
 Theophylline (theo-dur - for treating COPD, asthma)
PHARMACOKINETICS AND AGING
 Pharmacokinetics means “What the body does to the
drug.”
 It refers to the following functions by which the body
processes medications:
 Absorption
 Distribution
 Metabolism
 Excretion
 Normal changes in these processes that occur with
aging increase the risk of adverse medication reactions
among older adults.
PHARMACOKINETICS AND AGING
 Absorption
 Age-related changes in the gastrointestinal tract and skin seem
to have little impact on medication usage.
 So fortunately, there is not much to worry about here, however,
this is not the case for other components of medication
metabolism…
PHARMACOKINETICS AND AGING
 Distribution
 Important age-related changes:
 Decrease in lean body mass and total body water.
 Increased percentage body fat.
 Increase in volume of distribution for fat-dissolving drugs, such
as sedatives (I.e. valium, dalmane, librium) that penetrate the
central nervous system.
 This means older adults need most lower dosages of such
medications to achieve a therapeutic effect; they are at risk
for toxicity at doses considered normal for younger persons.
 Protein-binding changes with aging are of modest significance
for most drugs, especially at steady-state (when the amount of
drug going in is the same as the amount of drug going out).
PHARMACOKINETICS AND AGING
 Metabolism
 Many medications are processed by the liver.
 Although liver function is relatively unchanged with age, there
is some overall decline in metabolic capacity.
 Plus, many of the chronic conditions common among older
adults do negatively impact liver function.
 Decreased liver mass and hepatic blood flow lead to:
 High variability with no good estimation algorithms for doctors
to determine appropriate medication dosages for older adults.
 Minimal clinical manifestations of actual underlying problems,
so it is difficult for doctors to determine when someone may be
having problems.
PHARMACOKINETICS AND AGING
 Renal Excretion
 Medications are eliminated from the body via the kidneys and
urinary system.
 Age-related decreases in renal blood flow and kidney function
(specifically, glomerular filtration rate) impact older adults’
ability to eliminate medications.
 In addition, decreased lean body mass leads to decreased
creatinine production (a measure of kidney function, with high
levels being a cause for concern), thus, for older adults serum
creatinine may appear normal even when significant renal
impairment exists!
PHARMACODYNAMICS AND AGING
 Pharmacodynamics is the opposite of pharmacokinetics;
it refers to “What the drug does to the body.”
 Generally, lower drug doses are required to achieve the
same effect with advancing age.
 This is because:
 Receptor numbers, affinity, or post-receptor cellular effects
may change with age.
 Changes in homeostatic mechanisms can increase or
decrease drug sensitivity.
PHARMACODYNAMICS AND AGING
 Panels of experts in pharmacology and geriatrics have
compiled lists of medications to avoid prescribing for
patients 65 years of age or older.
 The most commonly used list is the Beers criteria, which
include 48 "potentially inappropriate medications" (PIMs)
for which there are more effective or safer alternatives
for older patients (Fick, et al, 2003).
PHARMACODYNAMICS AND AGING
 However in spite of the Beers criteria:
 Numerous studies in the last 15 years have found that PIMs
continue to be used in 12% to 40% of older patients in
community and nursing home settings (Raebel, Charles,
Dugan, & et al, 2007).
 Administrative data from nearly 400 hospitals across the United
States reveals that nearly half of all older patients hospitalized
for 7 common conditions were prescribed at least 1 PIM
(Rothberg et al, 2008).
PHARMACODYNAMICS AND AGING
 Such irrational polypharmacy can arise from several
factors:
 The prescriber hesitates to discontinue medications the patient
has been taking a long time.
 The prescriber may add more drugs to the patient's regimen
without removing any.
 The prescriber orders medication to alleviate adverse reactions
to other medications.
 he patient may be influenced by anecdotal reports touting the
benefits of certain medications.
MEDICATION NON-ADHERENCE
 Sometimes being on multiple medications contributes to
patients not taking those medications as the physician
intended.
 Not taking medications as prescribed.
 Correlates more strongly with number of meds, rather
than age.
 It is important to recognize that medication non-
adherence is a two-way street!
 Physician factors play a role.
 Patient factors play a role.
MEDICATION NON-ADHERENCE
 Example contributing factors:
 Patients
 Underreporting symptoms
 Use of multiple providers
 Use of others’ medications
 Physicians
 Limited time for discussion, diagnostics
 Limited knowledge of geriatric pharmacology
 The power of inertia
MEDICATION NON-ADHERENCE
 Additional contributing factors:
 Large number of medications
 Cost and other social barriers
 Complexity of medication regimen or frequently changing
medication schedule
 Adverse reactions (ADRs)
 Confusion about brand name/trade name
 Difficult-to-open containers
 Rectal, vaginal, subcutaneous modes of administration
 Lack of insight into illness
 Limited patient understanding of medication’s purpose
 Cognitive impairment/psych issues
 Illiteracy, language/cultural issues
 Misunderstanding verbal instructions
MEDICATION NON-ADHERENCE
 Like polypharmacy itself, the strongest predictor of
medication non-adherence is the number of
medications.
 Non-adherence rates are estimated at 25-50 percent of
older adults.
 Non-adherence is intentional about 75% of the time.
 33-69% of drug-related admissions result from non-
adherence (for all patients)
 Patients discharged with 4 or more meds- over 50% error
rate
 Changes in medication regimen made by patients to:
 Increase convenience
 Reduce adverse effects
SOLUTIONS TO POLYPHARMACY
 Review medication
 Anticipate Adverse Drug Events ( ADEs)
 Avoid errors- prescribe carefully
 Give verbal and written instructions
 Simplify
 Understand obstacles (cost, memory loss…)
 Enlist family/nursing/PCP
 Make sure there is good follow up
ALWAYS REMEMBER
 “Prescribing cascade”- a drug added to treat
(mistakenly) the ADR of another drug.
 Clinical Pearl- “Any symptom in an elderly person should
be evaluated as a potential ADR until proven otherwise”.
 Many geriatric syndromes can occur as a consequence
of medications: delirium, falls and fractures,
incontinence.
ALWAYS REMEMBER
 Polypharmacy is a reality of prescribing when patients
have multiple comorbidities.
 We must all anticipate and guard against the potential
complications of polypharmacy.
 Optimal prescribing is key!

More Related Content

What's hot

Frailty presentation
Frailty presentationFrailty presentation
Frailty presentationlenalutz
 
OVERVIEW OF GERIATRIC SYNDROMES 2016.ppt
OVERVIEW OF GERIATRIC SYNDROMES 2016.pptOVERVIEW OF GERIATRIC SYNDROMES 2016.ppt
OVERVIEW OF GERIATRIC SYNDROMES 2016.pptFeniksRetails
 
Comprehensive geriatric assessment
Comprehensive geriatric assessmentComprehensive geriatric assessment
Comprehensive geriatric assessmentAparna Chaudhary
 
The comprehensive geriatric assessment pcp slides
The comprehensive geriatric assessment  pcp slidesThe comprehensive geriatric assessment  pcp slides
The comprehensive geriatric assessment pcp slidesMarc Evans Abat
 
What's Geriatrics
What's GeriatricsWhat's Geriatrics
What's GeriatricsBabu Appat
 
Geriatric Medicine.ppt
Geriatric Medicine.pptGeriatric Medicine.ppt
Geriatric Medicine.pptShama
 
Assessment of the Geriatric Patient
Assessment of the Geriatric PatientAssessment of the Geriatric Patient
Assessment of the Geriatric PatientPAFP
 
The Aging Gastrointestinal Tract
The Aging Gastrointestinal TractThe Aging Gastrointestinal Tract
The Aging Gastrointestinal TractMegan Myrdal
 
Losing Weight For Unexplained Reasons - Dr Vivek Baliga Patient Presentation
Losing Weight For Unexplained Reasons - Dr Vivek Baliga Patient PresentationLosing Weight For Unexplained Reasons - Dr Vivek Baliga Patient Presentation
Losing Weight For Unexplained Reasons - Dr Vivek Baliga Patient PresentationDr Vivek Baliga
 
Guillain barre syndrome
Guillain barre syndromeGuillain barre syndrome
Guillain barre syndromePraveen Nagula
 
Comprehensive geriatric assessment
Comprehensive geriatric assessmentComprehensive geriatric assessment
Comprehensive geriatric assessmentDivya Jishnu
 
Wilson's disease (wilson)
Wilson's disease (wilson)Wilson's disease (wilson)
Wilson's disease (wilson)mahadev deuja
 
Restless leg syndrome
Restless leg syndromeRestless leg syndrome
Restless leg syndromeNeurologyKota
 

What's hot (20)

Frailty presentation
Frailty presentationFrailty presentation
Frailty presentation
 
OVERVIEW OF GERIATRIC SYNDROMES 2016.ppt
OVERVIEW OF GERIATRIC SYNDROMES 2016.pptOVERVIEW OF GERIATRIC SYNDROMES 2016.ppt
OVERVIEW OF GERIATRIC SYNDROMES 2016.ppt
 
Geriatrics
GeriatricsGeriatrics
Geriatrics
 
Frailty as a long term condition
Frailty as a long term conditionFrailty as a long term condition
Frailty as a long term condition
 
Comprehensive geriatric assessment
Comprehensive geriatric assessmentComprehensive geriatric assessment
Comprehensive geriatric assessment
 
Geriatrics
Geriatrics Geriatrics
Geriatrics
 
The comprehensive geriatric assessment pcp slides
The comprehensive geriatric assessment  pcp slidesThe comprehensive geriatric assessment  pcp slides
The comprehensive geriatric assessment pcp slides
 
What's Geriatrics
What's GeriatricsWhat's Geriatrics
What's Geriatrics
 
Aging-related Changes
Aging-related ChangesAging-related Changes
Aging-related Changes
 
2. physiologic changes in elderly
2. physiologic changes in elderly2. physiologic changes in elderly
2. physiologic changes in elderly
 
Geriatric Medicine.ppt
Geriatric Medicine.pptGeriatric Medicine.ppt
Geriatric Medicine.ppt
 
Assessment of the Geriatric Patient
Assessment of the Geriatric PatientAssessment of the Geriatric Patient
Assessment of the Geriatric Patient
 
The Aging Gastrointestinal Tract
The Aging Gastrointestinal TractThe Aging Gastrointestinal Tract
The Aging Gastrointestinal Tract
 
Losing Weight For Unexplained Reasons - Dr Vivek Baliga Patient Presentation
Losing Weight For Unexplained Reasons - Dr Vivek Baliga Patient PresentationLosing Weight For Unexplained Reasons - Dr Vivek Baliga Patient Presentation
Losing Weight For Unexplained Reasons - Dr Vivek Baliga Patient Presentation
 
Guillain barre syndrome
Guillain barre syndromeGuillain barre syndrome
Guillain barre syndrome
 
Comprehensive geriatric assessment
Comprehensive geriatric assessmentComprehensive geriatric assessment
Comprehensive geriatric assessment
 
Wilson's disease (wilson)
Wilson's disease (wilson)Wilson's disease (wilson)
Wilson's disease (wilson)
 
Restless leg syndrome
Restless leg syndromeRestless leg syndrome
Restless leg syndrome
 
Diabetic neuropathy
Diabetic neuropathyDiabetic neuropathy
Diabetic neuropathy
 
Pain in the elderly
Pain in the elderlyPain in the elderly
Pain in the elderly
 

Similar to Geriatric Syndromes

Frailty in older adults: Myths and Facts
Frailty in older adults: Myths and FactsFrailty in older adults: Myths and Facts
Frailty in older adults: Myths and FactsDoha Rasheedy
 
Demencia 2010
Demencia 2010Demencia 2010
Demencia 2010E. Avalos
 
Ch. 2 Comparing Vulnerable GroupsLearning ObjectivesAfter re.docx
Ch. 2 Comparing Vulnerable GroupsLearning ObjectivesAfter re.docxCh. 2 Comparing Vulnerable GroupsLearning ObjectivesAfter re.docx
Ch. 2 Comparing Vulnerable GroupsLearning ObjectivesAfter re.docxcravennichole326
 
National Institute on AgingNational Institutes of HealthU..docx
National Institute on AgingNational Institutes of HealthU..docxNational Institute on AgingNational Institutes of HealthU..docx
National Institute on AgingNational Institutes of HealthU..docxvannagoforth
 
1_Chapter_1_Understanding_Disability_&_Vulnerability_FINAL.ppt
1_Chapter_1_Understanding_Disability_&_Vulnerability_FINAL.ppt1_Chapter_1_Understanding_Disability_&_Vulnerability_FINAL.ppt
1_Chapter_1_Understanding_Disability_&_Vulnerability_FINAL.pptahmedmustefa773
 
Health Profile for Elderly
Health Profile for ElderlyHealth Profile for Elderly
Health Profile for ElderlyOtenciano
 
Chapter 2 Outline
Chapter 2 OutlineChapter 2 Outline
Chapter 2 Outlinemdoroteo
 
Epidemiology impact of aging
Epidemiology impact of agingEpidemiology impact of aging
Epidemiology impact of agingEusivia Pasi
 
Class 8, Part I Aging And Health Care
Class 8, Part I Aging And Health CareClass 8, Part I Aging And Health Care
Class 8, Part I Aging And Health Carejcarlson1
 
Research Findings on Mental Health
Research Findings on Mental HealthResearch Findings on Mental Health
Research Findings on Mental HealthGoInspiredJa
 
Children with disabilities
Children with disabilities Children with disabilities
Children with disabilities Soha Rashed
 
HLSU195 Adult Nursing.docx
HLSU195 Adult Nursing.docxHLSU195 Adult Nursing.docx
HLSU195 Adult Nursing.docxwrite4
 
MS_task_01_proposal for activity
MS_task_01_proposal for activityMS_task_01_proposal for activity
MS_task_01_proposal for activityGarth Richards
 
MULTIPLE DISABILITIES.pptx
MULTIPLE DISABILITIES.pptxMULTIPLE DISABILITIES.pptx
MULTIPLE DISABILITIES.pptxMonojitGope
 
Geriatrics.ppt ghtfeetyuhfetujhfrhfswuihf
Geriatrics.ppt ghtfeetyuhfetujhfrhfswuihfGeriatrics.ppt ghtfeetyuhfetujhfrhfswuihf
Geriatrics.ppt ghtfeetyuhfetujhfrhfswuihfZarakiyami
 

Similar to Geriatric Syndromes (20)

Frailty in older adults: Myths and Facts
Frailty in older adults: Myths and FactsFrailty in older adults: Myths and Facts
Frailty in older adults: Myths and Facts
 
Age
AgeAge
Age
 
Demencia 2010
Demencia 2010Demencia 2010
Demencia 2010
 
Ch. 2 Comparing Vulnerable GroupsLearning ObjectivesAfter re.docx
Ch. 2 Comparing Vulnerable GroupsLearning ObjectivesAfter re.docxCh. 2 Comparing Vulnerable GroupsLearning ObjectivesAfter re.docx
Ch. 2 Comparing Vulnerable GroupsLearning ObjectivesAfter re.docx
 
National Institute on AgingNational Institutes of HealthU..docx
National Institute on AgingNational Institutes of HealthU..docxNational Institute on AgingNational Institutes of HealthU..docx
National Institute on AgingNational Institutes of HealthU..docx
 
1_Chapter_1_Understanding_Disability_&_Vulnerability_FINAL.ppt
1_Chapter_1_Understanding_Disability_&_Vulnerability_FINAL.ppt1_Chapter_1_Understanding_Disability_&_Vulnerability_FINAL.ppt
1_Chapter_1_Understanding_Disability_&_Vulnerability_FINAL.ppt
 
Health Profile for Elderly
Health Profile for ElderlyHealth Profile for Elderly
Health Profile for Elderly
 
Chapter 2 Outline
Chapter 2 OutlineChapter 2 Outline
Chapter 2 Outline
 
Epidemiology impact of aging
Epidemiology impact of agingEpidemiology impact of aging
Epidemiology impact of aging
 
Class 8, Part I Aging And Health Care
Class 8, Part I Aging And Health CareClass 8, Part I Aging And Health Care
Class 8, Part I Aging And Health Care
 
Disabilities
DisabilitiesDisabilities
Disabilities
 
Disabilities
DisabilitiesDisabilities
Disabilities
 
World Mental Health Day 2013
World Mental Health Day 2013 World Mental Health Day 2013
World Mental Health Day 2013
 
Research Findings on Mental Health
Research Findings on Mental HealthResearch Findings on Mental Health
Research Findings on Mental Health
 
Children with disabilities
Children with disabilities Children with disabilities
Children with disabilities
 
HLSU195 Adult Nursing.docx
HLSU195 Adult Nursing.docxHLSU195 Adult Nursing.docx
HLSU195 Adult Nursing.docx
 
MS_task_01_proposal for activity
MS_task_01_proposal for activityMS_task_01_proposal for activity
MS_task_01_proposal for activity
 
MULTIPLE DISABILITIES.pptx
MULTIPLE DISABILITIES.pptxMULTIPLE DISABILITIES.pptx
MULTIPLE DISABILITIES.pptx
 
Geriatrics.ppt ghtfeetyuhfetujhfrhfswuihf
Geriatrics.ppt ghtfeetyuhfetujhfrhfswuihfGeriatrics.ppt ghtfeetyuhfetujhfrhfswuihf
Geriatrics.ppt ghtfeetyuhfetujhfrhfswuihf
 
Audience
AudienceAudience
Audience
 

More from Farhad Zargari

Dietary Supplements, a Glance at Global Trends
Dietary Supplements, a Glance at Global TrendsDietary Supplements, a Glance at Global Trends
Dietary Supplements, a Glance at Global TrendsFarhad Zargari
 
Pharmaceutical Contract Manufacturing
Pharmaceutical Contract ManufacturingPharmaceutical Contract Manufacturing
Pharmaceutical Contract ManufacturingFarhad Zargari
 
تحلیل پنج نیروی رقابتی پورتر، Porter five forces analysis
تحلیل پنج نیروی رقابتی پورتر، Porter five forces analysisتحلیل پنج نیروی رقابتی پورتر، Porter five forces analysis
تحلیل پنج نیروی رقابتی پورتر، Porter five forces analysisFarhad Zargari
 
Health as a Human Right in Islam-Part 7
Health as a Human Right in Islam-Part 7    Health as a Human Right in Islam-Part 7
Health as a Human Right in Islam-Part 7 Farhad Zargari
 
Health as a Human Right in Islam-Part 6
Health as a Human Right in Islam-Part 6 Health as a Human Right in Islam-Part 6
Health as a Human Right in Islam-Part 6 Farhad Zargari
 
Health as a Human Right in Islam-Part 5
Health as a Human Right in Islam-Part 5Health as a Human Right in Islam-Part 5
Health as a Human Right in Islam-Part 5Farhad Zargari
 
Health as a Human Right in Islam-Part 4
Health as a Human Right in Islam-Part 4 Health as a Human Right in Islam-Part 4
Health as a Human Right in Islam-Part 4 Farhad Zargari
 
Health as a Human Right in Islam-Part 3
Health as a Human Right in Islam-Part 3       Health as a Human Right in Islam-Part 3
Health as a Human Right in Islam-Part 3 Farhad Zargari
 
Health as a Human Right in Islam-Part 2
Health as a Human Right in Islam-Part 2 Health as a Human Right in Islam-Part 2
Health as a Human Right in Islam-Part 2 Farhad Zargari
 
Health as a Human Right in Islam-Part 1
Health as a Human Right in Islam-Part 1Health as a Human Right in Islam-Part 1
Health as a Human Right in Islam-Part 1Farhad Zargari
 
نقش نخبگان و متخصصین در حکمرانی خوب
نقش نخبگان و متخصصین در حکمرانی خوبنقش نخبگان و متخصصین در حکمرانی خوب
نقش نخبگان و متخصصین در حکمرانی خوبFarhad Zargari
 
Luke Fields, the Doctor
Luke Fields, the Doctor   Luke Fields, the Doctor
Luke Fields, the Doctor Farhad Zargari
 
Aging and New Disease Pattern
Aging and New Disease PatternAging and New Disease Pattern
Aging and New Disease PatternFarhad Zargari
 
Biological Basis of Aging
Biological Basis of AgingBiological Basis of Aging
Biological Basis of AgingFarhad Zargari
 

More from Farhad Zargari (20)

Dietary Supplements, a Glance at Global Trends
Dietary Supplements, a Glance at Global TrendsDietary Supplements, a Glance at Global Trends
Dietary Supplements, a Glance at Global Trends
 
Iran pharma workshop
Iran pharma workshopIran pharma workshop
Iran pharma workshop
 
Pharmaceutical Contract Manufacturing
Pharmaceutical Contract ManufacturingPharmaceutical Contract Manufacturing
Pharmaceutical Contract Manufacturing
 
تحلیل پنج نیروی رقابتی پورتر، Porter five forces analysis
تحلیل پنج نیروی رقابتی پورتر، Porter five forces analysisتحلیل پنج نیروی رقابتی پورتر، Porter five forces analysis
تحلیل پنج نیروی رقابتی پورتر، Porter five forces analysis
 
Health as a Human Right in Islam-Part 7
Health as a Human Right in Islam-Part 7    Health as a Human Right in Islam-Part 7
Health as a Human Right in Islam-Part 7
 
Health as a Human Right in Islam-Part 6
Health as a Human Right in Islam-Part 6 Health as a Human Right in Islam-Part 6
Health as a Human Right in Islam-Part 6
 
Health as a Human Right in Islam-Part 5
Health as a Human Right in Islam-Part 5Health as a Human Right in Islam-Part 5
Health as a Human Right in Islam-Part 5
 
Health as a Human Right in Islam-Part 4
Health as a Human Right in Islam-Part 4 Health as a Human Right in Islam-Part 4
Health as a Human Right in Islam-Part 4
 
Health as a Human Right in Islam-Part 3
Health as a Human Right in Islam-Part 3       Health as a Human Right in Islam-Part 3
Health as a Human Right in Islam-Part 3
 
Health as a Human Right in Islam-Part 2
Health as a Human Right in Islam-Part 2 Health as a Human Right in Islam-Part 2
Health as a Human Right in Islam-Part 2
 
Health as a Human Right in Islam-Part 1
Health as a Human Right in Islam-Part 1Health as a Human Right in Islam-Part 1
Health as a Human Right in Islam-Part 1
 
Health Literacy
Health LiteracyHealth Literacy
Health Literacy
 
نقش نخبگان و متخصصین در حکمرانی خوب
نقش نخبگان و متخصصین در حکمرانی خوبنقش نخبگان و متخصصین در حکمرانی خوب
نقش نخبگان و متخصصین در حکمرانی خوب
 
از دل Az Del
از دل Az Delاز دل Az Del
از دل Az Del
 
Luke Fields, the Doctor
Luke Fields, the Doctor   Luke Fields, the Doctor
Luke Fields, the Doctor
 
Aging and New Disease Pattern
Aging and New Disease PatternAging and New Disease Pattern
Aging and New Disease Pattern
 
Aging Demographics
Aging DemographicsAging Demographics
Aging Demographics
 
Biological Basis of Aging
Biological Basis of AgingBiological Basis of Aging
Biological Basis of Aging
 
Definition of Aging
Definition of AgingDefinition of Aging
Definition of Aging
 
aging
agingaging
aging
 

Recently uploaded

Master the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga TrainingMaster the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga TrainingJoga Yoga Training
 
CHAPTER- 1 SEMESTER V NATIONAL-POLICIES-AND-LEGISLATION.pdf
CHAPTER- 1 SEMESTER V NATIONAL-POLICIES-AND-LEGISLATION.pdfCHAPTER- 1 SEMESTER V NATIONAL-POLICIES-AND-LEGISLATION.pdf
CHAPTER- 1 SEMESTER V NATIONAL-POLICIES-AND-LEGISLATION.pdfSachin Sharma
 
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptxUrinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptxAnushriSrivastav
 
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...aunty1x2
 
Integrated Mother and Neonate Childwood Illness Health Care
Integrated Mother and Neonate Childwood Illness  Health CareIntegrated Mother and Neonate Childwood Illness  Health Care
Integrated Mother and Neonate Childwood Illness Health CareASKatoch1
 
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptxNose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptxDr. Rabia Inam Gandapore
 
Occupational Therapy Management for Parkinson's Disease - Webinar 2024
Occupational Therapy Management for Parkinson's Disease - Webinar 2024Occupational Therapy Management for Parkinson's Disease - Webinar 2024
Occupational Therapy Management for Parkinson's Disease - Webinar 2024Phinoj K Abraham
 
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdfDemystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdfSasikiranMarri
 
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptxASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptxAnushriSrivastav
 
pathology seminar presentation best ppt by .pptx
pathology seminar presentation best ppt by  .pptxpathology seminar presentation best ppt by  .pptx
pathology seminar presentation best ppt by .pptxAmanuelIbrahim
 
Cell structure slideshare.pptx Unlocking the Secrets of Cells: Structure, Fun...
Cell structure slideshare.pptx Unlocking the Secrets of Cells: Structure, Fun...Cell structure slideshare.pptx Unlocking the Secrets of Cells: Structure, Fun...
Cell structure slideshare.pptx Unlocking the Secrets of Cells: Structure, Fun...ananyagirishbabu1
 
Digital Healthcare: The Future of Medical Consultations
Digital Healthcare: The Future of Medical ConsultationsDigital Healthcare: The Future of Medical Consultations
Digital Healthcare: The Future of Medical Consultationssmartcare
 
Myopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptxMyopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptxRitonDeb1
 
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
 
Importance of Diet on Dental Health.docx
Importance of Diet on Dental Health.docxImportance of Diet on Dental Health.docx
Importance of Diet on Dental Health.docxSachin Mittal
 
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...aunty1x1
 
Enhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdfEnhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdfgajendrasinh1303
 
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...GQ Research
 
Virtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdfVirtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdfsmartcare
 
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur aunty1x1
 

Recently uploaded (20)

Master the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga TrainingMaster the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga Training
 
CHAPTER- 1 SEMESTER V NATIONAL-POLICIES-AND-LEGISLATION.pdf
CHAPTER- 1 SEMESTER V NATIONAL-POLICIES-AND-LEGISLATION.pdfCHAPTER- 1 SEMESTER V NATIONAL-POLICIES-AND-LEGISLATION.pdf
CHAPTER- 1 SEMESTER V NATIONAL-POLICIES-AND-LEGISLATION.pdf
 
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptxUrinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
 
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
 
Integrated Mother and Neonate Childwood Illness Health Care
Integrated Mother and Neonate Childwood Illness  Health CareIntegrated Mother and Neonate Childwood Illness  Health Care
Integrated Mother and Neonate Childwood Illness Health Care
 
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptxNose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
 
Occupational Therapy Management for Parkinson's Disease - Webinar 2024
Occupational Therapy Management for Parkinson's Disease - Webinar 2024Occupational Therapy Management for Parkinson's Disease - Webinar 2024
Occupational Therapy Management for Parkinson's Disease - Webinar 2024
 
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdfDemystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
 
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptxASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
 
pathology seminar presentation best ppt by .pptx
pathology seminar presentation best ppt by  .pptxpathology seminar presentation best ppt by  .pptx
pathology seminar presentation best ppt by .pptx
 
Cell structure slideshare.pptx Unlocking the Secrets of Cells: Structure, Fun...
Cell structure slideshare.pptx Unlocking the Secrets of Cells: Structure, Fun...Cell structure slideshare.pptx Unlocking the Secrets of Cells: Structure, Fun...
Cell structure slideshare.pptx Unlocking the Secrets of Cells: Structure, Fun...
 
Digital Healthcare: The Future of Medical Consultations
Digital Healthcare: The Future of Medical ConsultationsDigital Healthcare: The Future of Medical Consultations
Digital Healthcare: The Future of Medical Consultations
 
Myopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptxMyopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptx
 
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
 
Importance of Diet on Dental Health.docx
Importance of Diet on Dental Health.docxImportance of Diet on Dental Health.docx
Importance of Diet on Dental Health.docx
 
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
 
Enhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdfEnhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdf
 
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
 
Virtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdfVirtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdf
 
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
 

Geriatric Syndromes

  • 3. GERIATRIC SYNDROMES  1-Disability  2-Dementia and Delirium  3-Falls  4-Poly-pharmacy  5-Pressure Ulcers  6-Urinary Incontinence
  • 5. 1-LONGER LIVES AND DISABILITY  Are we living healthier as well as longer lives, or are our additional years spent in poor health? There is considerable debate about this question among researchers, and the answers have broad implications for the growing number of older people around the world. One way to examine the question is to look at changes in rates of disability, one measure of health and function.
  • 6. 1-LONGER LIVES AND DISABILITY  Disability is part of the human condition. Almost everyone will be temporarily or permanently impaired at some point in life, and those who survive to old age will experience increasing difficulties in functioning.
  • 7. 1-LONGER LIVES AND DISABILITY  Disability is the umbrella term for impairments, activity limitations and participation restrictions, referring to the negative aspects of the interaction between an individual (with a health condition) and that individual’s contextual factors (environmental and personal factors).
  • 8. 1-LONGER LIVES AND DISABILITY  Disability is “an evolving concept”, also “disability results from the interaction between persons with impairments and attitudinal and environmental barriers that hinder their full and effective participation in society on an equal basis with others”. Defining disability as an interaction means that “disability” is not an attribute of the person.
  • 9. 1-LONGER LIVES AND DISABILITY  Responses to disability have changed since the 1970s, prompted largely by the self-organization of people with disabilities, and by the growing tendency to see disability as a human rights issue. Historically, people with disabilities have largely been provided for through solutions that segregate them, such as residential institutions and special schools. Policy has now shifted towards community and educational inclusion, and medically- focused solutions have given way to more interactive approaches recognizing that people are disabled by environmental factors as well as by their bodies.
  • 10. 1-LONGER LIVES AND DISABILITY  Disability encompasses the child born with a congenital condition such as cerebral palsy or the young soldier who loses his leg to a land-mine, or the middle-aged woman with severe arthritis, or the older person with dementia, among many others.
  • 11. DISABILITY AND HUMAN RIGHTS  Disability is a human rights issue because:  People with disabilities experience inequalities – for example, when they are denied equal access to health care, employment, education, or political participation because of their disability.  People with disabilities are subject to violations of dignity – for example, when they are subjected to violence, abuse, prejudice, or disrespect because of their disability.  Some people with disability are denied autonomy – for example, when they are subjected to involuntary sterilization, or when they are confined in institutions against their will, or when they are regarded as legally incompetent because of their disability.
  • 12. DISABILITY AND DEVELOPMENT  Disability is a development issue, because of its bidirectional link to poverty: disability may increase the risk of poverty, and poverty may increase the risk of disability. A growing body of empirical evidence from across the world indicates that people with disabilities and their families are more likely to experience economic and social disadvantage than those without disability.
  • 13. 1-LONGER LIVES AND DISABILITY  Some researchers think there will be a decrease in the prevalence of disability as life expectancy increases, termed a “compression of morbidity.” Others see an “expansion of morbidity”—an increase in the prevalence of disability as life expectancy increases. Yet others argue that, as advances in medicine slow the progression from chronic disease to disability, severe disability will lessen, but milder chronic diseases will increase.
  • 14. 1-LONGER LIVES AND DISABILITY  In the United States, between 1982 and 2001 severe disability fell about 25 percent among those aged 65 or older even as life expectancy increased. This very positive trend suggests that we can affect not only how long we live, but also how well we can function with advancing age. Unfortunately, this trend may not continue in part because of rising obesity among those now entering older ages.
  • 15. 1-LONGER LIVES AND DISABILITY  The analysis of the Global Burden of Disease estimates that 15.3% of the world population (some 978 million people of the estimated 6.4 billion in 2004 had “moderate or severe disability”, while 2.9% or about 185 million experienced “severe dis- ability”. Among those aged 0–14 years, the figures were 5.1% and 0.7%, or 93 million and 13 million children, respectively. Among those 15 years and older, the figures were 19.4% and 3.8%, or 892 million and 175 million, respectively.
  • 16. 1-LONGER LIVES AND DISABILITY  Based on 2010 population estimates – 6.9 billion with 5.04 billion 15 years and over and 1.86 billion under 15 years – and 2004 disability prevalence estimates (World Health Survey and Global Burden of Disease) there were around 785 (15.6%) to 975 (19.4%) million persons 15 years and older living with disability. Of these, around 110 (2.2%) to 190 (3.8%) million experienced significant difficulties in functioning. Including children, over a billion people (or about 15% of the world’s population) were estimated to be living with disability.
  • 17. 1-LONGER LIVES AND DISABILITY  Fig. 2.1. Global disability prevalence estimates from different sources: This figure compares the population-weighted average prevalence of disability for high-income, middle- income, and low-income countries from multiple sources. The solid grey bars show the average prevalence based on available data, the range lines indicate the 10th and 90th percentiles for available country prevalence within each income group. The data used for this figure are not age standardized and cannot be directly compared with Table 2.1 and Table 2.3. WHS = World Health Survey; GBD = the
  • 18. 1-LONGER LIVES AND DISABILITY  Age-specific disability prevalence, derived from multi- domain functioning levels in 59 countries, by country income level and sex:
  • 19. 1-LONGER LIVES AND DISABILITY  Age-specific disability prevalence, derived from multi- domain functioning levels in 59 countries, by country income level and sex:
  • 20. 1-LONGER LIVES AND DISABILITY
  • 21. 1-LONGER LIVES AND DISABILITY  American adults reported worse health than did European adults as indicated by the presence of chronic diseases and by measures of disability. At all levels of wealth, Americans were less healthy than their European counterparts. Analyses of the same data sources also showed that cognitive functioning declined further between ages 55 and 65 in countries where workers left the labor force at early ages, suggesting that engagement in work might help preserve cognitive functioning.
  • 22. 1-LONGER LIVES AND DISABILITY  Prevalence of Chronic Disease and Disability among Men and Women Aged 50-74 Years in the United States, England, and Europe: 2004 Source: Adapted from Avendano M, Glymour MM, Banks J, Mackenbach JP. Health disadvantage in US adults aged 50
  • 23. REHABILITATION  Rehabilitation as “a set of measures that assist individuals who experience, or are likely to experience, disability to achieve and maintain optimal functioning in interaction with their environments”. A distinction is sometimes made between habilitation, which aims to help those who acquire disabilities con- genitally or early in life to develop maximal functioning; and rehabilitation, where those who have experienced a loss in function are assisted to regain maximal functioning.
  • 25. 2-THE BURDEN OF DEMENTIA  Physicians often define dementia based on the criteria given in the Diagnostic and Statistical Manual of Mental Disorders (DSM). In 2013 the American Psychiatric Association released the fifth edition of the DSM (DSM-5), which incorporates dementia into the diagnostic categories of major and mild neurocognitive disorders.
  • 26. 2-THE BURDEN OF DEMENTIA  To meet DSM-5 criteria for major neurocognitive disorder, an individual must have evidence of significant cognitive decline (for example, decline in memory, language or learning), and the cognitive decline must interfere with independence in everyday activities (for example, assistance may be needed with complex activities such as paying bills or managing medications). To meet DSM-5 criteria for mild neurocognitive disorder, an individual must have evidence of modest cognitive decline, but the decline does not interfere with everyday activities (individuals can still perform complex activities such as paying bills or managing medications, but the activities require greater effort).
  • 27. 2-THE BURDEN OF DEMENTIA  Dementia is a syndrome due to disease of the brain – usually of a chronic or progressive nature – in which there is disturbance of multiple higher cortical functions, including memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. Consciousness is not clouded. The impairments of cognitive function are commonly accompanied, and occasionally preceded, by deterioration in emotional control, social behavior, or motivation. This syndrome occurs in a large number of conditions primarily or secondarily affecting the brain.
  • 28. 2-THE BURDEN OF DEMENTIA  The cause of most dementia is unknown, but the final stages of this disease usually means a loss of memory, reasoning, speech, and other cognitive functions. The risk of dementia increases sharply with age and, unless new strategies for prevention and management are developed, this syndrome is expected to place growing demands on health and long term care providers as population ages.
  • 29. 2-THE BURDEN OF DEMENTIA  The disease is not easy to diagnose, especially in its early stages. The memory problems, misunderstandings, and behavior common in the early and intermediate stages are often attributed to normal effects of aging, accepted as personality traits, or simply ignored.
  • 30. 2-THE BURDEN OF DEMENTIA  Many cases remain undiagnosed even in the intermediate, more serious stages. A cross-national assessment conducted by the Organization for Economic Cooperation and Development (OECD) estimated that dementia affected about 10 million people in OECD member countries around 2000, just under 7 percent of people aged 65 or older.
  • 31. 2-THE BURDEN OF DEMENTIA
  • 32. 2-THE BURDEN OF DEMENTIA
  • 33. 2-THE BURDEN OF DEMENTIA
  • 34. 2-THE BURDEN OF DEMENTIA
  • 35. 2-THE BURDEN OF DEMENTIA
  • 36. 2-THE BURDEN OF DEMENTIA  Types of Dementia  Alzheimer’s disease  Vascular dementia=Post-stroke dementia  Dementia with Lewy bodies (DLB)  Frontotemporal lobar degeneration (FTLD)  Mixed dementia  Parkinson’s disease (PD) dementia  CreutzfeldtJakob disease  Normal pressure hydrocephalus
  • 37. 2-THE BURDEN OF DEMENTIA  The total number of people with dementia worldwide in 2010 is estimated at 35.6 million and is projected to nearly double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. The total number of new cases of dementia each year worldwide is nearly 7.7 million, implying one new case every four seconds.
  • 38. 2-THE BURDEN OF DEMENTIA  The total estimated worldwide costs of dementia were US$ 604 billion in 2010. In high-income countries, informal care (45%) and formal social care (40%) account for the majority of costs, while the proportionate contribution of direct medical costs (15%) is much lower. In low-income and lower-middle-income countries direct social care costs are small, and informal care costs (i.e. unpaid care provided by the family) predominate.
  • 39. 2-THE BURDEN OF DEMENTIA  Alzheimer’s disease(AD) is the most common form of dementia and accounted for between two-fifth and four fifth of all dementia cases cited in the OECD report. More recent analyses have estimated the worldwide number of people living with AD/dementia at between 27 million and 36 million. The prevalence of AD and other dementias is very low at younger ages, then nearly doubles with every five years of age after age 65.
  • 40. 2-THE BURDEN OF DEMENTIA  In the OECD review, for example, dementia affected fewer than 3 percent of those aged 65 to 69, but almost 30 percent of those aged 85 to 89. More than one-half of women aged 90 or older had dementia in France and Germany, as did about 40 percent in the United States, and just under 30 percent in Spain.
  • 41. 2-THE BURDEN OF DEMENTIA  The projected costs of caring for the growing numbers of people with dementia are daunting. The 2010 World Alzheimer Disease Report estimates that the total worldwide cost of dementia exceeded US$600 billion in 2010, including informal care provided by family and others, social care provided by community care professionals, and direct costs of medical care. Family members often play a key caregiving role, especially in the initial stages of what is typically a slow decline. Ten years ago, U.S. researchers estimated that the annual cost of informal caregiving for dementia in the United States was US$18 billion.
  • 42. 2-THE BURDEN OF DEMENTIA  The complexity of the disease and the wide variety of living arrangements can be difficult for people and families dealing with dementia, and countries must cope with the mounting financial and social impact. The challenge is even greater in the less developed world, where an estimated two-thirds or more of dementia sufferers live but where few coping resources are available.
  • 43. 2-THE BURDEN OF DEMENTIA  Projections by World Alzheimer Disease Report suggest that 115 million people worldwide will be living with AD/dementia in 2050, with a markedly increasing proportion of this total in less developed countries.
  • 44. 2-THE BURDEN OF DEMENTIA  The Growth of Numbers of People with Dementia in High- income Countries and Low- and Middle- income Countries: 2010-2050 Source: Alzheimer’s Disease International, World Alzheimer Report, 2010.
  • 46. HELP! I’VE FALLEN AND I CAN’T GET UP!
  • 47. 3-GERIATRIC FALLS  Falls are the leading cause of external injuries.  Most common in children less than 5 years old and adults 65 and older.  Trauma is the 5th cause of death in those >65 years  Falls are responsible for 70% of accidental deaths in people over 75 years old.  1/4 of the elderly people who fracture their hips die within 6 months of the injury.  35%-40% of people 65+ fall each year. Those who fall are 2-3 times more likely to fall again.  10%-20% of falls cause serious injuries.
  • 48. 3-GERIATRIC FALLS  Falls are the leading cause of external injuries.  Most common in children less than 5 years old and adults 65 and older.  Trauma is the 5th cause of death in those >65 years.  Falls are responsible for 70% of accidental deaths in people over 75 years old.  1/4 of the elderly people who fracture their hips die within 6 months of the injury.
  • 49. 3-GERIATRIC FALLS  Up to 20-30% of falls in older adults result in an injury requiring medical care  Most fractures in Medicare population are due to falls  Falls in older adults are the leading cause of traumatic brain injury  Men have a higher rate of fatal falls (due to TBI)  Women are more likely to have non-fatal falls
  • 50. 3-GERIATRIC FALLS Age Group First Leading of Trauma Death Second Leading Cause of Death 35 – 64 Motor Vehicle 36.8% Falls 29.6% 65+ Falls 43.3% Motor Vehicle 10.2%
  • 51. 3-GERIATRIC FALLS  Consequences of Geriatric Falls  Death  Injury  Fractures 10-15%  Hip 1-2%  Long Lie  Fear of Falling  Reduced Activity/Independence (25%)
  • 52. 3-GERIATRIC FALLS-HIP FRACTURE  In 1996 more than 250,000 older Americans had fractured hips.  90% are associated with falls  Excess of $10 billion  Leading fall-related injury that results in hospitalization – which are often prolonged and costly.  What Happens After the Hip Fracture?  One in four people that have a hip fracture that lived independently before the fracture had to live in a nursing home for a year afterward, according to the CDC.  Some never recover their balance and strength.  This can lead to depression and dementia and a downhill spiral.  Unfortunately 1/4 of the elderly people who fracture their hips die within 6 months of the injury.
  • 53. 3-GERIATRIC FALLS-BRAIN INJURY  Also a common injury following a fall  Many elderly on “blood thinners”  Symptoms may be subtle and not apparent at the time of injury.
  • 54. RISK FACTORS FOR FALLS  Increased age  Living alone  Previous falls  Use of a cane or walker  Acute illness  Reduced vision  Glare intolerance  Altered depth perception  Decreased night vision  Decline in peripheral vision
  • 55. RISK FACTORS FOR FALLS  CVA that results in hemiparesis, sensory and/or motor function deficits.  Decreased range of motion and flexibility in lower legs and spine.  Weakness  Decreased step length (short shuffling steps)  Alzheimer’s or dementia  Arthritis  Parkinson’s disease  Foot problems  Toenail length, callouses, bunions, deformities
  • 56. RISK FACTORS FOR FALLS  Difficulty rising from a chair  Neurologic changes  Slowed reaction times  Diminished sensory awareness for light touch, vibration, and temperature  Decline in proprioception  Decreased hearing  Impaired speech discrimination  Excessive cerumen accumulation  Loss of high frequency tones  Risky behaviors
  • 57. RISK FACTORS FOR FALLS  Medications  Some antidepressants  Sedatives  Some antihypertensive and cardiac medications  Hypoglycemic drugs  Alcohol
  • 58. 3-GERIATRIC FALLS  American Geriatrics Society: Most Common Intrinsic Fall Risk Factors  Muscle weakness: 4.4  History of falls: 3.0  Gait or balance deficit: 2.9  Use of assistive device: 2.6  Visual deficit: 2.5  Arthritis: 2.4  Depression: 2.2  Cognitive impairment: 1.8  Age over 80 years: 1.7 Data from AGS Panel on Falls Prevention. Guideline for the prevention of falls in older persons. J Am Geriatr Soc 2001;49(5):664–72.
  • 60. POLYPHARMACY-DEFINITION  Polypharmacy means “many drugs.”  In practice, polypharmacy refers to the use of more medication than is clinically indicated or warranted.  Polypharmacy can result in a gradual accumulation of side effects and/or adverse drug reactions, which negatively effects elders’ health and well-being.
  • 61. POLYPHARMACY-DEFINITION  Polypharmacy is the use of four or more medications by a patient, generally adults aged over 65 years. Polypharmacy (ie, the use of multiple medications and/or the administration of more medications than are clinically indicated, representing unnecessary drug use) is common among the elderly, affecting about 40% of older adults living in their own homes.
  • 62. POLYPHARMACY-DEFINITION  Although polypharmacy can be appropriate, it is more often inappropriate. Concerns about polypharmacy include increased adverse drug reactions, drug interactions, prescribing cascade, and higher costs. Polypharmacy is often associated with a decreased quality of life, decreased mobility and cognition.
  • 63. POLYPHARMACY-DEFINITION  Patients at greatest risk for negative polypharmacy consequences include the elderly, psychiatric patients, patients taking five or more drugs concurrently, those with multiple physicians and pharmacies, recently hospitalized patients, individuals with concurrent comorbidities, low educational level, and those with impaired vision or dexterity.
  • 64. POLYPHARMACY-DEFINITION  The literature review found that polypharmacy continues to increase and is a known risk factor for important morbidity and mortality.
  • 65. POLYPHARMACY-DEFINITION  Older adults comprise 12% of the U.S. population, but use 35% of the prescription medications and 50 percent of the over-the-counter medications.  The average medication usage for persons over 65 is:  2 to 6 prescription drugs, plus …  1 to 3.4 over-the-counter medicines.  In 2011, 58 percent of adults 65 years or older reported taking 5 or more medications and 18% reported taking 10 or more (Slone Epidemiology Center).  The average American senior spends $870 annually for pharmaceuticals.
  • 66. POLYPHARMACY-CAUSES  1-Age:  Community elders- 90% > 1med; 40% > 5meds; 12% > 10meds.  Highest number of drugs per person in greater than 80 year olds
  • 67. POLYPHARMACY-CAUSES  2-Chronic Diseases:  Increased prevalence of somatic complaints and chronic disease
  • 68. POLYPHARMACY-CAUSES  3-Drug Regimen Changes:  New meds, different doses…  Changes from generic to brand- nomenclature, color and/or shape
  • 69. POLYPHARMACY-CAUSES  4-Providers – Patients Relationship:  The more the providers and physician visits, the more the number of medications patients take.  2/3 of all physician visits end with a prescription.  Expectations to receive medication is growing from the patient side.  Shortage in communicating with PCP about medications changes.  Self-treatment
  • 70. POLYPHARMACY-COMPLICATIONS  Polypharmacy leads to:  More adverse drug reactions.  Decreased adherence to drug regimens.  Higher rates of disease symptomatology.  (Unnecessary) drug expenses.  All of the above contribute to client distress and poorer quality of life, which are of great concerns.
  • 71. POLYPHARMACY-COMPLICATIONS  Polypharmacy leads to:  More adverse drug reactions (ADR).  Decreased adherence to drug regimens.  Higher rates of disease symptomatology.  (Unnecessary) drug expenses.  All of the above contribute to client distress and poorer quality of life, which are of great concerns.
  • 72. ADVERSE DRUG REACTIONS  Side effects: considered minor enough to allow continuation of therapy.  Adverse Drug Reactions (ADRs): May necessitate discontinuation of drug and require treatment of adverse event.
  • 73. ADVERSE DRUG REACTIONS  An adverse drug reaction (ADR) is defined as the unwanted, negative consequences associated with the use of a medications or medications.  Over 100,000 deaths a year are attributed to adverse drug reactions, making ADRs the fourth leading cause of death in the U.S. (Lazarou, Pomeranz, & Corey, 2009).  Other examples of ADRs include:  Peptic ulcers  Anemia  Deceased white blood cell production (which increases infection risk)  Liver damage  Kidney damage  Confusion/drowsiness (which can lead to falls and subsequent injuries)
  • 74. ADVERSE DRUG REACTIONS  About 3 to 7% of all hospital admissions in the United States are for treatment of adverse drug reactions.  Elderly 7 times more likely to have unwanted side effect and 2-3 times more likely to have ADRs  Adverse drug reactions occur during 10 to 20% of hospital admissions, and about 10 to 20% of these reactions are severe.  The most consistent risk factor for an adverse drug reactions is:  The number of drugs being taken.  Multiple medications is the factor most strongly correlated with increased risk of ADRs. Exponential increase in ADRs with addition of more drugs to a
  • 75. ADVERSE DRUG REACTIONS 1 10 100 0 2 4 6 8 10 12 14 16 18 20 number of drugs taken percentofpatientswithADR
  • 76. ADVERSE DRUG REACTIONS  Other risk factors for ADRs include:  Having six or more chronic diseases.  Taking twelve or more doses of medication (of any type) per day.  Taking nine or more medications total.  Having had a prior adverse drug reaction.  Being older than 85 years (this is important because persons 85 and older are the fastest growing segment of the population).  Having decreased kidney function.
  • 77. ADVERSE DRUG REACTIONS  Drugs most frequently associated with adverse reactions in the elderly:  Psychotropic drugs, especially benzodiazepines (valium, ativan)  Anti-hypertensive agents (blood pressure medications)  Diuretics  Digoxin (a heart medication)  NSAIDS (Non-steroidal anti-inflammatory drugs, i.e. aspirin, Aleve, celebrex)  Corticosteroids (i.e. prednisone - often used to treat arthritis)  Warfarin (coumadin - a blood thinner for treating blood clots)  Theophylline (theo-dur - for treating COPD, asthma)
  • 78. PHARMACOKINETICS AND AGING  Pharmacokinetics means “What the body does to the drug.”  It refers to the following functions by which the body processes medications:  Absorption  Distribution  Metabolism  Excretion  Normal changes in these processes that occur with aging increase the risk of adverse medication reactions among older adults.
  • 79. PHARMACOKINETICS AND AGING  Absorption  Age-related changes in the gastrointestinal tract and skin seem to have little impact on medication usage.  So fortunately, there is not much to worry about here, however, this is not the case for other components of medication metabolism…
  • 80. PHARMACOKINETICS AND AGING  Distribution  Important age-related changes:  Decrease in lean body mass and total body water.  Increased percentage body fat.  Increase in volume of distribution for fat-dissolving drugs, such as sedatives (I.e. valium, dalmane, librium) that penetrate the central nervous system.  This means older adults need most lower dosages of such medications to achieve a therapeutic effect; they are at risk for toxicity at doses considered normal for younger persons.  Protein-binding changes with aging are of modest significance for most drugs, especially at steady-state (when the amount of drug going in is the same as the amount of drug going out).
  • 81. PHARMACOKINETICS AND AGING  Metabolism  Many medications are processed by the liver.  Although liver function is relatively unchanged with age, there is some overall decline in metabolic capacity.  Plus, many of the chronic conditions common among older adults do negatively impact liver function.  Decreased liver mass and hepatic blood flow lead to:  High variability with no good estimation algorithms for doctors to determine appropriate medication dosages for older adults.  Minimal clinical manifestations of actual underlying problems, so it is difficult for doctors to determine when someone may be having problems.
  • 82. PHARMACOKINETICS AND AGING  Renal Excretion  Medications are eliminated from the body via the kidneys and urinary system.  Age-related decreases in renal blood flow and kidney function (specifically, glomerular filtration rate) impact older adults’ ability to eliminate medications.  In addition, decreased lean body mass leads to decreased creatinine production (a measure of kidney function, with high levels being a cause for concern), thus, for older adults serum creatinine may appear normal even when significant renal impairment exists!
  • 83. PHARMACODYNAMICS AND AGING  Pharmacodynamics is the opposite of pharmacokinetics; it refers to “What the drug does to the body.”  Generally, lower drug doses are required to achieve the same effect with advancing age.  This is because:  Receptor numbers, affinity, or post-receptor cellular effects may change with age.  Changes in homeostatic mechanisms can increase or decrease drug sensitivity.
  • 84. PHARMACODYNAMICS AND AGING  Panels of experts in pharmacology and geriatrics have compiled lists of medications to avoid prescribing for patients 65 years of age or older.  The most commonly used list is the Beers criteria, which include 48 "potentially inappropriate medications" (PIMs) for which there are more effective or safer alternatives for older patients (Fick, et al, 2003).
  • 85. PHARMACODYNAMICS AND AGING  However in spite of the Beers criteria:  Numerous studies in the last 15 years have found that PIMs continue to be used in 12% to 40% of older patients in community and nursing home settings (Raebel, Charles, Dugan, & et al, 2007).  Administrative data from nearly 400 hospitals across the United States reveals that nearly half of all older patients hospitalized for 7 common conditions were prescribed at least 1 PIM (Rothberg et al, 2008).
  • 86. PHARMACODYNAMICS AND AGING  Such irrational polypharmacy can arise from several factors:  The prescriber hesitates to discontinue medications the patient has been taking a long time.  The prescriber may add more drugs to the patient's regimen without removing any.  The prescriber orders medication to alleviate adverse reactions to other medications.  he patient may be influenced by anecdotal reports touting the benefits of certain medications.
  • 87. MEDICATION NON-ADHERENCE  Sometimes being on multiple medications contributes to patients not taking those medications as the physician intended.  Not taking medications as prescribed.  Correlates more strongly with number of meds, rather than age.  It is important to recognize that medication non- adherence is a two-way street!  Physician factors play a role.  Patient factors play a role.
  • 88. MEDICATION NON-ADHERENCE  Example contributing factors:  Patients  Underreporting symptoms  Use of multiple providers  Use of others’ medications  Physicians  Limited time for discussion, diagnostics  Limited knowledge of geriatric pharmacology  The power of inertia
  • 89. MEDICATION NON-ADHERENCE  Additional contributing factors:  Large number of medications  Cost and other social barriers  Complexity of medication regimen or frequently changing medication schedule  Adverse reactions (ADRs)  Confusion about brand name/trade name  Difficult-to-open containers  Rectal, vaginal, subcutaneous modes of administration  Lack of insight into illness  Limited patient understanding of medication’s purpose  Cognitive impairment/psych issues  Illiteracy, language/cultural issues  Misunderstanding verbal instructions
  • 90. MEDICATION NON-ADHERENCE  Like polypharmacy itself, the strongest predictor of medication non-adherence is the number of medications.  Non-adherence rates are estimated at 25-50 percent of older adults.  Non-adherence is intentional about 75% of the time.  33-69% of drug-related admissions result from non- adherence (for all patients)  Patients discharged with 4 or more meds- over 50% error rate  Changes in medication regimen made by patients to:  Increase convenience  Reduce adverse effects
  • 91. SOLUTIONS TO POLYPHARMACY  Review medication  Anticipate Adverse Drug Events ( ADEs)  Avoid errors- prescribe carefully  Give verbal and written instructions  Simplify  Understand obstacles (cost, memory loss…)  Enlist family/nursing/PCP  Make sure there is good follow up
  • 92. ALWAYS REMEMBER  “Prescribing cascade”- a drug added to treat (mistakenly) the ADR of another drug.  Clinical Pearl- “Any symptom in an elderly person should be evaluated as a potential ADR until proven otherwise”.  Many geriatric syndromes can occur as a consequence of medications: delirium, falls and fractures, incontinence.
  • 93. ALWAYS REMEMBER  Polypharmacy is a reality of prescribing when patients have multiple comorbidities.  We must all anticipate and guard against the potential complications of polypharmacy.  Optimal prescribing is key!